This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOOKIPA Pharma (HOOK) in Focus: Stock Moves 8.4% Higher
by Zacks Equity Research
HOOKIPA Pharma (HOOK) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
HOOKIPA (HOOK) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
HOOKIPA (HOOK) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
New Strong Sell Stocks for November 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 39.13% and 138.32%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why HOOKIPA (HOOK) Stock Might be a Great Pick
by Zacks Equity Research
HOOKIPA (HOOK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
HOOKIPA Pharma Inc (HOOK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc (HOOK) delivered earnings and revenue surprises of -10.26% and -15.13%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will HOOKIPA Pharma Inc (HOOK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
HOOKIPA Pharma Inc (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.